Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
Matthew J. Frigault, Michael R. Bishop, Jacalyn Rosenblatt, et al.
Blood Advances (2022) Vol. 7, Iss. 5, pp. 768-777
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Challenges and new technologies in adoptive cell therapy
Pengchao Zhang, Guizhong Zhang, Xiaochun Wan
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 74
Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future
Sarah A. Holstein, Shakira J. Grant, Tanya M. Wildes
Journal of Clinical Oncology (2023) Vol. 41, Iss. 27, pp. 4416-4429
Open Access | Times Cited: 44
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
Li Lu, Mingqi Xie, Bo Yang, et al.
Science Advances (2024) Vol. 10, Iss. 8
Open Access | Times Cited: 18
Dose–response correlation for CAR-T cells: a systematic review of clinical studies
Anand Rotte, Matthew J. Frigault, Ayub Ansari, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005678-e005678
Open Access | Times Cited: 46
Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
Jessica S Little, Megha Tandon, Joseph Hong, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5485-5495
Open Access | Times Cited: 23
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
Dian Zhou, Qian Sun, Jieyun Xia, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 10, pp. e751-e760
Closed Access | Times Cited: 13
Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
Mariam Markouli, Fauzia Ullah, Serhan Ünlü, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6330-6352
Open Access | Times Cited: 21
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
Zhengyu Yu, Hexian Li, Qizhong Lu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Aina Oliver‐Caldés, Marta Español‐Rego, Aintzane Zabaleta, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2085-2096
Closed Access | Times Cited: 7
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Paola Neri, Noémie Leblay, Holly Lee, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 590-609
Closed Access | Times Cited: 7
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial
Nathalie Asherie, Shlomit Kfir‐Erenfeld, Batia Avni, et al.
Haematologica (2022) Vol. 108, Iss. 7, pp. 1827-1839
Open Access | Times Cited: 22
Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments
Matthew A. Nix, Arun P. Wiita
Cytotherapy (2024) Vol. 26, Iss. 7, pp. 729-738
Open Access | Times Cited: 5
Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations
Beatriz Martín-Antonio, Belén Blanco, África González‐Murillo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access
Targeting BCMA in multiple myeloma: designs, challenges, and future directions
Yi Hu, Yuetao Xie, Xiaodong Wang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 3
Open Access
Allogeneic chimeric antigen receptors (CARs) as an “off-the-shelf” therapy in multiple myeloma
Sophie G. Carlson, Tasha Lin, Sarah Larson
Immunotherapy (2025), pp. 1-12
Open Access
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
Chia Jie Tan, Dylan Kacerek, Nattawara Kampirapawong, et al.
Cancer Medicine (2025) Vol. 14, Iss. 5
Open Access
Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
Lina Zhang, Xuxing Shen, Wenjun Yu, et al.
Annals of Medicine (2021) Vol. 53, Iss. 1, pp. 1547-1559
Open Access | Times Cited: 27
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
Norah Sadek, Bruno Almeida Costa, Karthik Nath, et al.
Clinical Pharmacology & Therapeutics (2023)
Closed Access | Times Cited: 12
Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
K. Connolly, Daniel Brungs, E. Szeto, et al.
Current Oncology (2013) Vol. 21, Iss. 1, pp. 151-151
Open Access | Times Cited: 41
Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials
Dingyuan Hu, Liming Chen, Diqin Yan, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
Role of Immune Cells and Immunotherapy in Multiple Myeloma
V. Radhakrishnan, Upendarrao Golla, Avinash K. Kudva
Life (2024) Vol. 14, Iss. 4, pp. 461-461
Open Access | Times Cited: 3
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Dawn Swan, Deepu Madduri, Jane S. Hocking
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
Massimo Martino, Virginia Naso, Barbara Loteta, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13332-13332
Open Access | Times Cited: 14
Controlling CAR-T cell activity and specificity with synthetic SparX adapters
Justin P. Edwards, Jeffrey S. Swers, Janine M. Buonato, et al.
Molecular Therapy (2024) Vol. 32, Iss. 6, pp. 1835-1848
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top